177 related articles for article (PubMed ID: 15684572)
1. [Relationship between dose of mycophenolate mofetil and the occurrence of cytomegalovirus infection and diarrhea in renal transplant recipients].
Toda T; Motoki T; Kurosawa N; Owada E; Achiwa K; Yuhki Y; Tadano K; Takahashi Y; Shimoda N; Shindo J; Harada H; Seki T; Hirano T
Yakugaku Zasshi; 2005 Feb; 125(2):177-85. PubMed ID: 15684572
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
3. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
7. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study.
Sarmiento JM; Munn SR; Paya CV; Velosa JA; Nguyen JH
Clin Transplant; 1998 Oct; 12(5):371-4. PubMed ID: 9787943
[TBL] [Abstract][Full Text] [Related]
8. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?--A mini-review.
Song AT; Abdala E; Bonazzi PR; Bacchella T; Machado MC
Braz J Infect Dis; 2006 Apr; 10(2):132-8. PubMed ID: 16878265
[TBL] [Abstract][Full Text] [Related]
9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
10. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
11. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis.
Zhao YJ; Wen JQ; Cheng K; Ming YZ; She XG; Liu H; Liu L; Ye QF; Ding BN
Transplant Proc; 2013; 45(6):2226-32. PubMed ID: 23953533
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation.
Hambach L; Stadler M; Dammann E; Ganser A; Hertenstein B
Bone Marrow Transplant; 2002 Jun; 29(11):903-6. PubMed ID: 12080355
[TBL] [Abstract][Full Text] [Related]
13. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
Basic-Jukic N; Kes P; Bubic-Filipi LJ; Puretic Z; Brunetta B; Pasini J
Transplant Proc; 2005 Mar; 37(2):850-1. PubMed ID: 15848553
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients.
Roberti I; Reisman L
Pediatr Transplant; 1999 Aug; 3(3):231-5. PubMed ID: 10487285
[TBL] [Abstract][Full Text] [Related]
15. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
Satoh S; Tada H; Murakami M; Tsuchiya N; Inoue T; Togashi H; Matsuura S; Hayase Y; Suzuki T; Habuchi T
Transplant Proc; 2005 May; 37(4):1751-3. PubMed ID: 15919454
[TBL] [Abstract][Full Text] [Related]
16. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
[TBL] [Abstract][Full Text] [Related]
17. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
Kiberd BA; Lawen J; Daley C
Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
[TBL] [Abstract][Full Text] [Related]
18. Uncommon side effect of MMF in renal transplant recipients.
Balal M; Demir E; Paydas S; Sertdemir Y; Erken U
Ren Fail; 2005; 27(5):591-4. PubMed ID: 16152998
[TBL] [Abstract][Full Text] [Related]
19. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
[TBL] [Abstract][Full Text] [Related]
20. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
Hao C; Anwei M; Bing C; Baiyong S; Weixia Z; Chuan S; Erzhen C; Xiaxing D; Weihua Q; Weiping Y; Chenghong P; Hongwei L
Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
